Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31

Journal of the National Cancer Institute

Volumn 105, Issue 23, 2013, Pages 1782-1788

  Pogue Geile, Katherine L ^c   Kim, Chungyeul ^c   Jeong, Jong Hyeon ^b,d   Tanaka, Noriko ^c   Bandos, Hanna ^b,d   Gavin, Patrick G ^c   Fumagalli, Debora ^c   Goldstein, Lynn C ^e   Sneige, Nour ^f   Burandt, Eike ^g   Taniyama, Yusuke ^c   Bohn, Olga L ^c   Lee, Ahwon ^c,h   Kim, Seung Il ^c   Reilly, Megan L ^c   Remillard, Matthew Y ^c   Blackmon, Nicole L ^c   Kim, Seong Rim ^c   Horne, Zachary D ^c   Rastogi, Priya ^b,i   Fehrenbacher, Louis ^b,j   Romond, Edward H ^b,k   Swain, Sandra M ^b,l   Mamounas, Eleftherios P ^b,m   Wickerham, D Lawrence ^b,o   Geyer Jr , Charles E ^b,n   Costantino, Joseph P ^b,d   Wolmark, Norman ^b,o   Paik, Soonmyung ^a,b,p   more..

^a NSABP Foundation Inc   (United States)

^b National Surgical Adjuvant Breast   (United States)

^c NSABP   (United States)

^d UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^e PHENOPATH LABORATORIES   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^h The Catholic University of Korea   (South Korea)

ⁱ UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^j University of Kentucky ^*  (United States)

^k UNIVERSITY OF KENTUCKY   (United States)

^l WASHINGTON CANCER INSTITUTE   (United States)

^m M D ANDERSON CANCER CENTER ORLANDO   (United States)

ⁿ VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^o ALLEGHENY GENERAL HOSPITAL   (United States)

^p Yonsei University College of Medicine   (South Korea)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; GROWTH FACTOR RECEPTOR BOUND PROTEIN 7; MESSENGER RNA; PACLITAXEL; SOMATOMEDIN C RECEPTOR; TRANSCRIPTION FACTOR GATA 3; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; COHORT ANALYSIS; CONTROLLED STUDY; GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PRINCIPAL COMPONENT ANALYSIS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; RNA, MESSENGER; TREATMENT OUTCOME;

EID: 84890482594     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djt321     Document Type: Article

References (22)

1. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783-792.
2. Untch M, Rezai M, Loibl S, et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol. 2010;28(12):2024-2031.
3. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353(16):1659-1672.
4. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673-1684.
5. Paik S, Kim C, Wolmark N. HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med. 2008;358(3):1409-1411.
6. Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13(8):2329-2334.
7. Barok M, Isola J, Palyi-Krekk Z, et al. Trastuzumab causes antibodydependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. Mol Cancer Ther. 2007;6(7):2065-2072.
8. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med. 2000;6(4): 443-446.
9. Nakanishi T, Chumsri S, Khakpour N, et al. Side-population cells in luminal-Type breast cancer have tumour-initiating cell properties, and are regulated by HER2 expression and signalling. Br J Cancer. 2010;102(5): 815-826.
10. Ithimakin S, Day KC, Malik F, et al. HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab. Cancer Res. 2012;73(5):1635-1645.
11. Geiss GK, Bumgarner RE, Birditt B, et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol. 2008;26(3):317-325.
12. Bear HD, Anderson S, Smith RE, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2006;24(13):2019-2027.
13. Parker JS, Mullins M, Cheang MC, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27(8):1160-1167.
14. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-Treated, node-negative breast cancer. N Engl J Med. 2004;351(27):2817-2826.
15. Bonetti M, Gelber RD. Patterns of treatment effects in subsets of patients in clinical trials. Biostatistics (Oxford, England). 2004;5(3):465-481.
16. Lin DY, Wei LJ, Ying Z. Checking the Cox model with cumulative sums of Martingale-based residuals. Biometrika. 1993;80(3):557-572.
17. Bhargava R, Dabbs DJ, Beriwal S, et al. Semiquantitative hormone receptor level influences response to trastuzumab-containing neoadjuvant chemotherapy in HER2-positive breast cancer. Mod Pathol. 2011;24(3):367-374.
18. Kim C, Tang G, Pogue-Geile KL, et al. Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer. J Clin Oncol. 2011;29(31):4160-4167.
19. Huang X, Gao L, Wang S, et al. Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-I receptor in breast cancer cells resistant to herceptin. Cancer Res. 2010;70(3):1204-1214.
20. Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (herceptin). J Natl Cancer Inst. 2001;93(24):1852-1857.
21. Osborne CK, Wakeling A, Nicholson RI. Fulvestrant: An oestrogen receptor antagonist with a novel mechanism of action. Br J Cancer. 2004;90(Suppl 1):S2-S6.
22. Zhang S, Huang WC, Li P, et al. Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat Med. 2011;17(4):461-469.